Quantinno Capital Management LP Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Quantinno Capital Management LP boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 25.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,239 shares of the company’s stock after buying an additional 448 shares during the period. Quantinno Capital Management LP’s holdings in Neurocrine Biosciences were worth $258,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. 1832 Asset Management L.P. grew its position in shares of Neurocrine Biosciences by 1,370.7% in the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after purchasing an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after buying an additional 228,444 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after buying an additional 216,500 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after acquiring an additional 203,934 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $133.05 on Tuesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The business has a 50 day moving average price of $121.75 and a 200-day moving average price of $130.59. The firm has a market cap of $13.47 billion, a PE ratio of 35.79 and a beta of 0.34.

Wall Street Analyst Weigh In

Several research firms have issued reports on NBIX. Jefferies Financial Group increased their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $165.00.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.